Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group.
about
CMV in Hematopoietic Stem Cell TransplantationThe clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.Immunorestitution disease involving the innate and adaptive response.Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.Prevention and treatment of viral infections in stem cell transplant recipients.Beta-herpesvirus challenges in the transplant recipient.Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction.Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy.Cytomegalovirus in hematopoietic stem cell transplant recipientsReduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation PracticesClinical significance of low cytomegalovirus DNA levels in human plasma.Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients.Cytomegalovirus pneumonia in hematopoietic stem cell recipients.How we treat cytomegalovirus in hematopoietic cell transplant recipients.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Cytomegalovirus infection/disease after hematopoietic stem cell transplantation.Opportunistic viral infections in intestinal transplantation.The expanding role of therapeutic antibodies.Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.Viral Pneumonia in Patients with Hematologic Malignancy or Hematopoietic Stem Cell Transplantation.Human Cytomegalovirus Stimulates the Synthesis of Select Akt-Dependent Antiapoptotic Proteins during Viral Entry To Promote Survival of Infected Monocytes.Human Cytomegalovirus Induces an Atypical Activation of Akt To Stimulate the Survival of Short-Lived Monocytes.Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosineIntravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action.Herpes virus infections in immunocompromised patients: problems and therapeutic interventions.Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells.Valaciclovir: development, clinical utility and potential.Single-cell T-cell receptor-β analysis of HLA-A*2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT.Cytomegalovirus Treatment.Narrowing of T-cell receptor beta variable repertoire during symptomatic herpesvirus infection in transplant patients.Evaluation of interleukin-6 and interleukin-10 in lung transplant patients with human cytomegalovirus infection.Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation.Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation.Management of cytomegalovirus infection in haemopoietic stem cell transplantation.Studies of the pathogenesis of wild-type virus and six temperature-sensitive mutants of mouse cytomegalovirus.Sequential respiratory syncytial virus and cytomegalovirus pneumonia following bone marrow transplantation.Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells.Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation.
P2860
Q26740385-7512C1E0-A6AF-47A7-AE6E-738B9A11D21EQ33734872-7FF09FB8-4B2D-4CF6-8F6C-D4136235E3D3Q33958197-C146803C-4995-408E-BE7A-B32B620B2541Q34294838-8AF13A68-FECE-4ABD-AA28-4807614C3DEDQ34722706-FEEE2944-59C0-42CF-90CC-33D1039260E9Q34918418-9D4D06FF-CF75-403E-BF1D-D091F899B16AQ35732096-D6B12AC7-D83D-4CA3-A466-559F712FE23EQ35917480-67573BB5-FEE6-4D1F-87EE-5AEB5C6BEA54Q35922928-F800A52B-37AA-4145-BF48-E2D313D6DECAQ35975542-CB27EA9A-CD18-476A-9BF8-C8DBC40E9DD7Q36118750-B2861C56-793D-40DA-A001-44788BD0996EQ36889236-79990385-E23B-4B3B-AE9E-8466F2996B40Q37179131-5445A33A-A77D-499E-8FBB-C43C1C0886B8Q37237427-3D0AF8DE-DE7A-4004-B5B3-AFA73988D9E8Q37426542-EF349688-113F-40F7-B772-5596892C58CEQ37736316-B26CD12D-4CC4-49F3-82F4-64879105BEF7Q38097119-013B97F8-D8FF-4FB8-9CB4-202A81B6A6A3Q38182645-C0404C6B-01AC-4859-9A37-5AD46FDEA9F2Q38560786-E5B41AD7-BA34-4E7C-AE15-B54FF84C558BQ38835171-0556B255-8C62-4665-A759-ACC54B65F098Q39118448-CDFF76AB-81DB-4609-B7C2-1235BC76011CQ39601708-F3FB7288-C5BE-4B6F-81E1-132D323ED1CAQ39792977-B1E0FF87-39C8-4AC4-83E8-CA1993A041C9Q39864931-5925903B-F5BA-4409-AD59-807DB35B0A6EQ40703838-FC8CAAD9-46CC-48F5-8DB7-625C7A9D54D8Q40769917-983DADBD-CAC1-43B1-9232-A34A28D48E99Q40809435-5E74CCBB-F3C0-4994-8C99-FD8969483633Q40904060-EA387B38-0B73-44AC-A51E-A451657D6E1AQ42277578-1BCD668F-0EB2-4BCA-8FD5-7EA5DFF2CA83Q42554715-0888EB06-1D00-48D7-953A-522D9ED059A7Q43489588-2D96EDE1-D505-43D9-B2A2-E26CED29C9F8Q43920701-19B858BA-3579-429D-9089-C7004829DB6EQ43920822-CEFFB02C-077F-4D3F-B9D2-E606E1A53E9EQ44189939-3CFEB11A-BE89-4045-BC68-B44491844949Q44398534-8E1D6A00-3158-4E57-99DC-8843699F91E3Q44714539-4130A8E8-AA99-4E61-BF35-A0D7ED3577A1Q45782302-9FE3E386-3729-4CCF-9950-0A3FDF2FCE5DQ45787659-3B01BC6A-B0DC-4631-AC2A-9222268CE1E0Q46727960-DCC0ACE1-3F77-45A6-90AB-6B6AA92D2EA5Q47416112-8D33421C-8E8D-4AAD-8D00-B013E0C7DAAC
P2860
Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Treatment of interstitial pneu ...... Bone Marrow Transplant Group.
@en
Treatment of interstitial pneu ...... Bone Marrow Transplant Group.
@nl
type
label
Treatment of interstitial pneu ...... Bone Marrow Transplant Group.
@en
Treatment of interstitial pneu ...... Bone Marrow Transplant Group.
@nl
prefLabel
Treatment of interstitial pneu ...... Bone Marrow Transplant Group.
@en
Treatment of interstitial pneu ...... Bone Marrow Transplant Group.
@nl
P2093
P356
P1476
Treatment of interstitial pneu ...... Bone Marrow Transplant Group.
@en
P2093
A de Laurenzi
C Cordonnier
D Engelhard
L Debusscher
P304
P356
10.1093/CLINIDS/14.4.831
P407
P50
P577
1992-04-01T00:00:00Z